MRCHF
H.U. Group Holdings, Inc., through its subsidiaries, provides laboratory testing products and services in Japan. The company offers lab testing and its related services to medical institutions; self-medication services; food, environment, and cosmetic testing services; and testing services through corporate health insurance associations. It also researches, develops, manufactures, and sells in vitro diagnostic devices, which includes the LUMIPULSE, an automatic chemiluminescent enzyme immunoassay system that offers reagents for infectious disease, cancer, and lifestyle disease to medical institutions and testing centers; and ESPRINE, a rapid diagnostics kit series for influenza, hepatitis B, and the novel coronavirus, as well as supplies ingredients for test drugs. In addition, the company provides support services related to hospital administration work, including aid for surgical procedures and endoscope room work, inspection and maintenance services for medical equipment, and in-hospital logistics management and transportation services; and rents and sells nursing-care equipment and supplies. Further, it offers home-visit nursing care services. The company was formerly known as Miraca Holdings Inc. and changed its name to H.U. Group Holdings, Inc. in July 2020. H.U. Group Holdings, Inc. was incorporated in 1950 and is headquartered in Tokyo, Japan.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q4 | 22.37 | $61.0B | $8.9B |
| 2025 Q3 | 97.39 | $62.4B | $5.4B |
| 2025 Q2 | 25.03 | $63.9B | $5.1B |
| 2025 Q1 | -21.07 | $61.4B | -$152,658 |
| 2025 Q4 | -0.58 | $61.0B | $8.1B |
| 2024 Q3 | 63.62 | $62.1B | $5.5B |
| 2024 Q2 | -17.53 | $60.5B | $3.5B |
| 2024 Q1 | 3.08 | $59.5B |
| -$618M |